Me filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of ...

Israel’s strike on Iran rattled markets and raised fears of oil disruption — another reminder that in today’s economy, instability is always close at hand.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S. Bankruptcy Court for ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has agreed to acquire US-based Blueprint Medicines for up to US$9.5bn, marking ...

Monday’s moves come after the S&P 500 closed out the month of May with a more than 6% gain, its best monthly performance ...